Repare Therapeutics Inc.
RPTX
$2.12
-$0.01-0.24%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.87M | 250.00K | 1.07M | 53.48M | 66.52M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.87M | 250.00K | 1.07M | 53.48M | 66.52M |
| Cost of Revenue | -36.01M | -15.11M | 678.00K | 13.38M | 6.36M |
| Gross Profit | 47.88M | 15.36M | 395.00K | 40.10M | 60.17M |
| SG&A Expenses | 27.07M | 28.96M | 31.25M | 32.22M | 34.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 91.08M | 113.88M | 131.96M | 145.62M | 158.74M |
| Operating Income | -79.21M | -113.63M | -130.88M | -92.14M | -92.22M |
| Income Before Tax | -71.44M | -108.76M | -126.71M | -83.25M | -82.42M |
| Income Tax Expenses | 763.00K | 1.10M | 1.18M | 1.44M | 1.63M |
| Earnings from Continuing Operations | -72.20 | -109.86 | -127.89 | -84.69 | -84.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.20M | -109.86M | -127.89M | -84.69M | -84.05M |
| EBIT | -79.21M | -113.63M | -130.88M | -92.14M | -92.22M |
| EBITDA | -76.46M | -110.47M | -128.28M | -90.22M | -90.24M |
| EPS Basic | -1.69 | -2.58 | -3.01 | -1.99 | -1.98 |
| Normalized Basic EPS | -1.06 | -1.56 | -1.80 | -1.20 | -1.19 |
| EPS Diluted | -1.70 | -2.59 | -3.01 | -2.00 | -2.00 |
| Normalized Diluted EPS | -1.06 | -1.56 | -1.80 | -1.21 | -1.20 |
| Average Basic Shares Outstanding | 170.99M | 170.48M | 170.00M | 169.64M | 169.27M |
| Average Diluted Shares Outstanding | 171.08M | 170.48M | 170.00M | 171.43M | 171.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |